VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA

被引：0

作者：

Chin, A. ^{[1
]}

Ip, Q. ^{[1
]}

Wu, X. ^{[1
]}

Lyle, D. ^{[2
]}

机构：

[1] Komodo Hlth, San Francisco, CA USA

[2] NeoGenomics, Ft Myers, FL USA

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EPH56

引用

页码：S163 / S163

页数：1

共 50 条

[31] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
Jacobson, Anne
ONCOLOGIST, 2022, 27 : S11 - S12
[32] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
Guerrero-Zotano, Angel
Belli, Stefania
Zielinski, Christoph
Gil-Gil, Miguel
Fernandez-Serra, Antonio
Ruiz-Borrego, Manuel
Gil, Eva Maria Ciruelos
Pascual, Javier
Munoz-Mateu, Montserrat
Bermejo, Begon
Vila, Mireia Margeli
Anton, Antonio
Murillo, Laura
Nissenbaum, Bella
Liu, Yuan
Herranz, Jesus
Fernandez-Garcia, Daniel
Caballero, Rosalia
Lopez-Guerrero, Jose Antonio
Bianco, Roberto
Formisano, Luigi
Turner, Nicholas
Martin, Miguel
CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
[33] Impact of hormone receptor expression level in HR+/HER2-metastatic breast cancer in the large French ESME cohort
Alexandre, Marie
Castan, Florence
Rouge, Thibault De La Motte
Mailliez, Audrey
Brain, Etienne
Bachelot, Thomas
Arnedos, Monica
Dalenc, Florence
Ferrero, Jean-Marc
Massard, Vincent
Desmoulins, Isabelle
Mouret-Reynier, Marie-Ange
Levy, Christelle
Goncalves, Anthony
Berghian, Anca
Savoye, Aude-Marie
Frenel, Jean-Sebastien
Bosquet, Lise
Delaloge, Suzette
Jacot, William
CANCER RESEARCH, 2024, 84 (09)
[34] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer
Guerin, Annie
Goldschmidt, Debbie
Small, Tania
Gagnon-Sanschagrin, Patrick
Romdhani, Hela
Gauthier, Genevieve
Kelkar, Sneha
Wu, Eric Q.
Niravath, Polly
Dalal, Anand A.
ADVANCES IN THERAPY, 2018, 35 (08) : 1251 - 1264
[35] Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
Song, Yan
Hao, Yanni
Macalalad, Alexander R.
Lin, Peggy L.
Signorovitch, James E.
Wu, Eric Q.
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 67 - 72
[36] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
CANCER RESEARCH, 2017, 77
[37] Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain
Blancas, Isabel
Grosjean, Jessica
Pedersini, Rebecca
Buzzoni, Carlotta
Sleilaty, Ghassan
Molero, Alberto
Tamma, Antonella
Chouaki, Nadia
Atienza, Manuel
Emde, Anna
Siddi, Sara
Bayona, Rodrigo Sanchez
Del Mastro, Lucia
Fakhouri, Walid
FUTURE ONCOLOGY, 2024,
[38] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
Li, Nanxin
Du, Ella X.
Chu, Lihao
Peeples, Miranda
Xie, Jipan
Barghout, Victoria
Tang, Derek H.
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
[39] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
Hamilton, E. P.
Cortes, J.
Ozyilkan, O.
Chen, S-C.
Petrakova, K.
Manikhas, A.
Jerusalem, G.
Hegg, R.
Huober, J.
Chapman, S. C.
Yang, Z.
Chen, Y.
Johnston, E. L.
Martin, M.
ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
[40] PIK3CA Mutation Assessment in HR+/HER2-Metastatic Breast Cancer: Overview for Oncology Clinical Practice
Criscitiello, Carmen
Marra, Antonio
Curigliano, Giuseppe
JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (01): : 42 - 54

← 1 2 3 4 5 →